These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
754 related articles for article (PubMed ID: 38174814)
1. Maintenance therapy for chronic lymphocytic leukaemia. Lee CH; Wu YY; Huang TC; Lin C; Zou YF; Cheng JC; Chen PH; Jhou HJ; Ho CL Cochrane Database Syst Rev; 2024 Jan; 1(1):CD013474. PubMed ID: 38174814 [TBL] [Abstract][Full Text] [Related]
2. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. Bauer K; Rancea M; Roloff V; Elter T; Hallek M; Engert A; Skoetz N Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008079. PubMed ID: 23152253 [TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104 [TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab for patients with chronic lymphocytic leukaemia. Skoetz N; Bauer K; Elter T; Monsef I; Roloff V; Hallek M; Engert A Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD008078. PubMed ID: 22336834 [TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176 [TBL] [Abstract][Full Text] [Related]
7. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. Gaitskell K; Rogozińska E; Platt S; Chen Y; Abd El Aziz M; Tattersall A; Morrison J Cochrane Database Syst Rev; 2023 Apr; 4(4):CD007930. PubMed ID: 37185961 [TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751 [TBL] [Abstract][Full Text] [Related]
9. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002 [TBL] [Abstract][Full Text] [Related]
10. Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant. Langer P; John L; Monsef I; Scheid C; Piechotta V; Skoetz N Cochrane Database Syst Rev; 2024 May; 5(5):CD013595. PubMed ID: 38695605 [TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant treatment for stage III and IV cutaneous melanoma. Gorry C; McCullagh L; O'Donnell H; Barrett S; Schmitz S; Barry M; Curtin K; Beausang E; Barry R; Coyne I Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012974. PubMed ID: 36648215 [TBL] [Abstract][Full Text] [Related]